Web Research

Web Research — What the Internet Knows

The Bottom Line from the Web

Centene is mid-way through the worst crisis in its history. On July 1, 2025 the company withdrew full-year guidance after fresh ACA Marketplace actuarial data revealed enrollment was below plan and the risk pool sicker than priced; the stock dropped 40.4% to an 8-year low the next day, triggering a securities class action (Lunstrum v. Centene, 25-cv-05659 S.D.N.Y.) and an SEC investigation. Filings later confirmed a $6.7B goodwill impairment and 2025 adjusted EPS of just $2.08 versus a prior $7.25 guide. The single most important web-only finding: 2026 EPS guidance of >$3.00 is materially above peers (Molina lost 28% on its 2026 guide on the same day Centene reported), suggesting margin recovery is starting — but the next confirmation is Q1 2026 earnings tomorrow, April 28, 2026.

Price (4/24/26)

$41.82

Market Cap ($B)

20.6

LTM Return

-32.0%

FY2025 Adj EPS

$2.08

**Q1 2026 earnings drop tomorrow (April 28, 2026, pre-market).** This is the single most important confirmation event for the recovery thesis. Bull case: Medicaid HBR ≤93.7% confirms structural stabilization. Bear case: HBR re-acceleration breaks the >$3 EPS thesis and re-rates the stock toward analyst lows of $32.

What Matters Most

The top findings ranked by what would change an investor's view of CNC today.

1. July 2, 2025: 40% one-day crash — worst day in company history

On July 1, 2025 after-hours, Centene withdrew its full-year 2025 guidance after reviewing Wakely actuarial data from 22 of 29 ACA Marketplace states. Enrollment came in below expectations and the risk pool was sicker than priced. The company estimated a **$1.8B reduction to risk-adjustment receivables**, cutting EPS by $2.75 from a $7.25 guide. The stock fell from $56.65 to $33.78 on July 2 — a **40.4% single-day decline**, wiping out more than $11B of market cap and hitting an 8-year low. Sources: Investopedia (2025-07-02), Forbes (2025-07-02).

2. Active securities class action + SEC investigation

**Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.)** — class period December 12, 2024 to June 30, 2025. Plaintiffs allege Centene and senior executives violated §§10(b) and 20(a) by issuing "inflated guidance" while internal metrics did not match public optimism. Multiple firms (Kessler Topaz, Levi & Korsinsky, Hagens Berman, Robbins Geller, DJS Law Group, Faruqi, Rosen, BFA, Schall, Glancy Prongay) competed for lead plaintiff; deadline was September 8, 2025. Trefis explicitly flags "securities lawsuits and an SEC investigation over alleged misleading statements" as a key ongoing risk. Sources: ktmc.com, rgrdlaw.com, prnewswire.com (Hagens Berman, 2025-07-15), trefis.com.

3. $6.7B goodwill impairment, 2025 EPS collapsed 71% from initial guide

FY2025 GAAP diluted loss of $(13.53)/share, net loss of $6.67B, operating loss of $7.62B — driven primarily by a $6.7B non-cash goodwill impairment completed in October 2025 after the OBBB Act and stock decline triggered the test. Adjusted EPS of $2.08 was 71% below the initial $7.25 guide. Source: investors.centene.com (2026-02-06).

4. 2026 guidance: EPS above consensus, revenue below — first top-line decline

2026 adjusted EPS guidance **greater than $3.00** beat consensus and "set Centene apart from peers that have warned of persistent pressure from elevated medical costs" — Molina Healthcare's stock plunged 28% the same day on weak guidance. However, 2026 revenue guide of **$186.5B–$190.5B is below consensus $192.5B**, with premium and service revenue **falling to $170B–$174B** (from $174.6B in 2025). The mix signals a margin-recovery thesis, not growth. Sources: Reuters (2026-02-06), GuruFocus (2026-02-06), HealthcareDive.

5. Health Benefits Ratio blew out — 470bps deterioration

Q4 2025 HBR of 94.3% is among the worst in major MCO history — a 5.7% gross margin on premium revenue, leaving thin room for error. Drivers: Marketplace morbidity (sicker pool post-redeterminations), IRA-related PDP changes, and Medicaid behavioral health / home health / high-cost drug costs. Q4 Commercial HBR was 95.4% (100bps above expectations). 2026 guide assumes HBR 90.9%–91.7%. Sources: 2025 earnings release, Trefis.

6. Massive institutional flight in Q4 2025 — but selective adds into the drawdown

No Results

The most material Q4 2025 13F move: Politan Capital Management cut 70.4% (5.2M shares, ~$214.7M) — Politan was the activist that took a $900M stake in December 2021 and forced the Neidorff CEO exit. Their near-full exit is a meaningful negative governance signal. Norges Bank dumped 18.4M shares (-$757M) and UBS Asset Management dumped 14.8M (-$609M). Offsetting: AQR added 17.1M shares (+117%), Robeco +427%, T. Rowe +53%. Net: 426 institutions decreased vs. 452 increased; institutional ownership remains 93.6%.

7. Politan activist exit — Centene's largest governance shareholder unwound

**Politan Capital Management (Quentin Koffey) reduced its CNC position by 70.4% in Q4 2025** — selling roughly $215M. Politan took a ~$900M stake in December 2021 and used it to force a 2021 cooperation agreement adding 5 new directors (Burdick, Coughlin, DeVeydt, Samuels) and Neidorff's exit, replacing him with Sarah London. The activist's near-full exit signals diminishing confidence in the turnaround. Source: Reuters (2021-12-14), Quiver (2026-04-21).

8. Director Burdick sold $2.58M, CEO London bought $490K — mixed insider signal

No Results

CEO Sarah London bought 19,230 shares at $25.50 during the August 2025 crash — a ~$490K signal of confidence. Director Kenneth Burdick (ex-WellCare CEO) sold 66,007 shares in two open-market transactions for ~$2.58M with zero offsetting purchases over six months — the largest insider sell signal at the company. Across all CNC insiders in the past 6 months: 0 buys (open market), 2 sells.

9. Big Beautiful Bill + ACA subsidy expiration = structural Medicaid/Marketplace pressure

**OBBB Act (Trump's 2025 budget bill)** decreases Medicaid funding and adds work requirements (effective January 2027). Centene has the largest Medicaid concentration of any major MCO (~64% of members), making it the most exposed. Separately, **enhanced ACA premium tax credits expired at end of 2025** — WSJ reports approximately 1 in 7 ACA enrollees failed to make payments in 2026, hitting Centene's Ambetter franchise (~5.5M members). House Judiciary Republicans also subpoenaed eight ACA insurers (including Centene) over alleged ACA subsidy fraud. Sources: Yahoo Finance (2025-08), WSJ via TipRanks (2026-04-15), Reuters.

10. PBM/Envolve overcharging: $1B+ in cumulative state settlements still tail-risk

No Results

Centene's Envolve Pharmacy Solutions PBM has paid out roughly $1B+ across multiple states since 2021 for failing to pass drug-discount savings to state Medicaid programs. The 2022 proxy explicitly preserves uncertainty about whether "additional claims, reviews or investigations relating to our PBM business will be brought." The 2024 Florida settlement also drew controversy because $10M was routed to the politically-connected Hope Florida Foundation rather than the state. Sources: Reuters, DOJ press releases.

11. Leadership reshuffles — three reorgs in 18 months

> **April 6, 2026:** Two new Group President roles created — Daniel Finke (ex-Aetna president, ex-Convey CEO) for Markets & Commercial; Michael Carson promoted to Group President, Medicare & Specialty. > **March 18, 2026:** Theodore Pienkos appointed Corporate Controller / CAO (rotating Katie Casso out). > **March 24, 2026:** New finance leadership announced. > **January 2024:** Carson hired as Wellcare (Medicare) CEO. > **December 2022:** Brent Layton out, Ken Fasola in as president.

Multiple structural reorgs in 18 months suggests management is still scrambling for stability — not a settled turnaround. Source: investors.centene.com.

12. Buyback collapsed 84%; no dividend; debt remains investment grade

2025 buybacks of $475M were down 84% from $3.0B in 2024. Centene has never paid a dividend. Total debt at YE2025 was $17.4B with no revolver borrowings on the $4.0B facility. Debt/cap stood at 46.5% (up from ~39%) but well below the 60% covenant. Moody's rates senior notes Ba1 (speculative grade), stable outlook. New credit agreement signed March 6, 2025; April 2024 issued $700M of 5.000% notes due 2034 + $800M of 5.375% notes due 2054.

13. Analyst targets bifurcated $32–$75; consensus right at current price

No Results

Median consensus PT is approximately $41.5–$43.5 (StockAnalysis $39.50 mean; Fintel $47.42; TickerNerd median $44; range $32–$75). Recent direction is mixed but bottoming: Bernstein and Morgan Stanley raised targets in 1Q26; Goldman cut to $32 (Sell maintained); Jefferies raised slightly. Mizuho's $71→$40 cut on 2025-07-12 captures the magnitude of the post-Q2 reset.

14. Centene diverging positively from peers — first sign of stabilization

Reuters (2026-02-06): "Centene on Friday forecast 2026 profit above Wall Street expectations, **setting itself apart from peers** that have warned of persistent pressure from elevated medical costs. Molina Healthcare shares plunged more than 28% on Friday after the U.S. health insurer forecast 2026 profit at less than expected." Baird's Michael Ha noted Molina overhang would "prevent Centene from moving higher today" but the divergence in operational tone is the first concrete bullish signal in 12 months.

15. Glassdoor culture concerns — 3.7/5, recurring complaints about leadership

Centene Glassdoor rating is 3.7 out of 5 across 5,997 reviews; Comparably comp rating is C+. Recurring complaints in negative reviews include: "Corporate is a mess," "Hostile, Mean, and Corrupt Corporate Culture," "smile up & kick down" politics, "50–60 hours/week" expectations, "Going downhill," allegations of bullying managers and "questionable integrity," and disappointing benefits "considering how well executives are paid." A consistent theme: post-merger discontent at WellCare ("Before merging with Centene it was WellCare which was a GREAT company"). Headcount is 61,100 FTEs as of 12/31/2025.

Recent News Timeline

No Results

Page / 2 12 of 20 records

What the Specialists Asked

Insider Spotlight

No Results

Industry Context

The managed-care industry is mid-cycle on a margin reset that began with post-COVID Medicaid redeterminations exposing acuity-mismatched rates. Centene is the most Medicaid-concentrated of the major MCOs (~64% of members), making it most exposed to the OBBB Act's reduced Medicaid funding and 2027 work requirements, but also most leveraged to recovery if state rate updates true up to acuity.

Three industry-level forces dominate the 2026 outlook:

Medicare Advantage Stars/rate cycle — CMS finalized 2027 MA rate at 2.48% on April 6, 2026 versus a 0.09% preliminary January proposal; Centene rallied 5% on the news. Centene targets MA breakeven by 2027 with stars improvement (46% of members in 3.5+ star plans, up from 23%).
Enhanced ACA premium tax credits expired end of 2025 — the WSJ-reported 1-in-7 ACA non-payment rate hits Centene's Ambetter franchise (5.5M members) hardest. The House Judiciary subpoena over ACA subsidy fraud adds regulatory tail risk.
GLP-1 Medicare coverage — Trump's April 2026 plan to cover GLP-1s under Medicare is reported as a multi-billion-dollar cost burden for insurers; direct hit to Centene's PDP/MA businesses (8.12M PDP members at YE2025, +17% YoY).

Versus peers: Centene's 2026 EPS guide is the most positive among major MCOs — Molina dropped 28% on its 2026 guide the same day Centene's came out. UnitedHealth is described in industry coverage as "trading short-term margins for long-term moats." Cigna shows positive ROE/ROIC vs. Centene's -33.4% / -18.85%. Peers' tone supports the read that Centene is operationally stabilizing first.